Kelsey Goodwin
Stock Analyst at Guggenheim
(1.45)
# 1721
Out of 5,372 analysts
19
Total ratings
70.00%
Success rate
10.39%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
URGN UroGen Pharma | Maintains: Strong Buy | 15 30 | 13.98 | 114.59% | 3 | Jun 13, 2025 | |
IPSC Century Therapeutics | Reiterates: Buy | n/a | n/a | n/a | 3 | Mar 28, 2025 | |
GNLX Genelux | Initiates Coverage On: Buy | 8 | 3.12 | 156.41% | 1 | Oct 29, 2024 | |
NUVL Nuvalent | Maintains: Strong Buy | 99 105 | 76.54 | 37.18% | 2 | Sep 16, 2024 | |
MGNX Macrogenics | Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | n/a | n/a | n/a | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Oct 31, 2022 |